Posts

Actio’s remaining drug pipeline moves to Setara after Jazz buyout

on
Setara Biosciences has launched with $90 million in Series A financing to develop programs left outside Jazz Pharmaceuticals’ acquisition of Actio Biosciences. Jazz acquired Actio for $820 million upfront, primarily to obtain ABS-1230, an investigational treatment for KCNT1-related epilepsy. The deal also included potential additional payments, bringing the reported total value to about $1.3 billion. Setara’s lead program is STAR-0871, a TRPV4 inhibitor being developed for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder. The company also plans to advance earlier-stage programs in genetic epilepsies and other areas, including migraine. The financing included Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures; Jazz also became a Setara shareholder as part of the transaction. Actio founder David Goldstein will lead Setara, alongside several members of Actio’s former leadership team. Sources: Setara Biosciences Annou...

Lilly raises 2026 outlook as GLP-1 demand and Medicare Bridge access boost sales

on

AstraZeneca targets $1.5B in annual savings to reinvest in its pipeline

on

Sanofi weighs selective “moonshot” deals as it plans for the Dupixent patent cliff

on

Dren Bio raises $350 million to advance rare blood cancer drug

on

Flagship combines three biotech platforms to launch AI drug-discovery company Etcelera

on

Aspen raises $141M and Bambusa brings in $169M in biotech IPOs

on

FDA draft proposes a streamlined route for some patient-specific gene-editing therapies

on

Oura and UC San Diego Health launch smart-ring study of obesity treatment outcomes

on

HHS eases enforcement for six unapproved wellness peptides

on

Merck plans another investment-heavy year in 2027

on

Bristol Myers beats Q3 revenue estimates, but Cobenfy sales disappoint

on

LENZ cuts workforce as it shifts toward consumer marketing

on